InvestSMART

ReNerve Limited (ASX:RNV)

ALERT: Price-sensitive ASX Announcement for RNV
Current share price for RNV : $0.077 0.003 (4.05%)+
Announcement
Release
10 Aug 2026 10:44AM
Price at Release
$0.074
Full Release
download
Summary
ReNerve Limited, an Australian biotechnology company, has announced that it has secured marketing approval for its NervAlign® Nerve Cuff in India. This significant milestone was achieved in partnership with NetCentrix Ventures, a commercialization specialist in the Indian healthcare market. The approval, granted by India’s Central Drugs Standard Control Organization (CDSCO), allows for the commercial rollout of the NervAlign® Nerve Cuff across India, a country known for its large population and high incidence of road-trauma related nerve injuries. This marks ReNerve's first product approval in the Indian market, estimated to be valued at approximately USD $700 million by 2025. The company's CEO, Dr. Julian Chick, emphasized the importance of this achievement as a validation of their clinical data and the product's benefits, further positioning ReNerve as a leader in nerve repair solutions.
Key Points
  • ReNerve secures marketing approval in India for NervAlign® Nerve Cuff.
  • Approval granted by India's Central Drugs Standard Control Organization (CDSCO).
  • Partnership with NetCentrix Ventures for commercialization in India.
  • India offers a significant market opportunity with a large population and high road-trauma rates.
  • Indian nerve repair market projected to be valued at USD $700 million by 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.